New cancer screening technology from Madison-based biotech firm Exact Sciences is now available to the public.
With what the firm calls a “liquid biopsy” test, Cancerguard is “designed to detect more than 50 cancer types and subtypes” using blood samples, according to its website.
While the Cancerguard test is not yet approved by the U.S. Food and Drug Administration, some consumers can already request a prescription for it through their personal health care provider or online from Exact Sciences. The kit costs $689 and is not covered by health insurance…